Therefore, we propose that inhibiting lactyltransferases, such as AARS1 [29], rather than lactate synthesis itself, may lead to a more potent inhibitory effect in the treatment of ccRCC. The gene discussed is AARS1; the disease is nonpapillary renal cell carcinoma.